HOME >> BIOLOGY >> NEWS
Cells in mucus from lungs of high-risk patients can predict tumor development

In a group of high-risk patients, a test that examined DNA from cells expelled in sputum for evidence of "silenced" genes correctly identified the majority of patients who were later diagnosed with lung cancer, say researchers in a study published in the March 15 issue of Cancer Research.

As such, the sputum test potentially represents a unique, non-invasive, and cost-effective screening method that could lead to earlier treatment of lung cancer.

"Short of repeatedly X-raying a person's lungs to look for emerging tumors, there is no way now to screen people at high risk for lung cancer, much less predict who will be diagnosed with the cancer at a later date," said the study's senior author, Steven Belinsky, Ph.D., director of the Lung Cancer Program at the Lovelace Respiratory Research Institute in Albuquerque, N.M.

"When perfected and validated, this kind of test holds great promise for identifying people with lung cancer early enough to successfully treat them," he said.

The test was able to predict which patients would develop lung cancer up to 18 months later. Catching lung tumors within that short timeframe can change a patient's outcome, Belinsky said, because these cells often proliferate rapidly after a long slow-growth period.

"Because most people are diagnosed when their cancer is advanced, they may not benefit from surgery, chemotherapy or radiation, which is why median survival from diagnosis is only 13 months," he said. "But lung tumors that can be surgically removed are associated with a five year survival rate of more than 60 percent."

The researchers are now working to perfect the test because it is not yet accurate enough for the clinic. It identified 65 percent of individuals who later developed symptoms of lung cancer, but also tagged 35 percent of cancer-free control participants.

"Our hope is that our continuing research will identify additional genes that will make a sputum test like this
'"/>

Contact: Russell Vanderboom, Ph.D.
vanderboom@aacr.org
215-440-9300
American Association for Cancer Research
15-Mar-2006


Page: 1 2 3

Related biology news :

1. Cells take risks with their identities
2. Cells re-energize to come back from the brink of death
3. Need oxygen? Cells know how to spend and save
4. Cells selectively absorb short nanotubes
5. Cells use noise to make cell-fate decisions
6. Cells in the lung clear the air to prevent lung damage
7. Cells passed from mother to child during pregnancy live on and make insulin
8. Cells, dyes and videotape: Online scientific methods journal incorporates multimedia
9. Cells use mix-and-match approach to tailor regulation of genes
10. Double-trouble: Cells with duplicate genomes can trigger tumors
11. Double trouble: Cells with duplicate genomes can trigger tumors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/7/2020)... ... 07, 2020 , ... dicentra , a leading clinical ... and dietary supplement industries, announces 2020 membership with the International Probiotics Association (“IPA”). ... pertaining to probiotics. We are thrilled to join our IPA member colleagues and ...
(Date:2/5/2020)... ... February 04, 2020 , ... Crystal Diagnostics (CDx) ... a second patent related to proprietary liquid crystal technology for rapid and accurate ... the USPTO issued on December 3, 2019. Together, these patents protect the company’s ...
(Date:1/30/2020)... , ... January 30, 2020 , ... Accelera Canada ... eye on the Canadian market, is pleased to announce that the company has opened ... since the company launched in 2017. , “We are so thrilled to now ...
Breaking Biology News(10 mins):
(Date:1/27/2020)... , ... January 27, 2020 , ... ... it has secured financing from strategic investors led by Halma plc , ... existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal Implant ... surgery industry at two recent North American investor forums specializing in medical advancements. ... Medical Technologies & Diagnostics Forum on November 21, 2019 in New York City, ...
(Date:1/22/2020)... ... 21, 2020 , ... QCDx , a private biotech company that has ... today announced the sale of the proprietary RareScope™ instrument to the Carole and Ray ... clinical cancer research. , “The RareScope can detect and isolate intact and live Circulating ...
(Date:1/8/2020)... ... 2020 , ... Anomet Products has introduced new ... in harsh environments inside or outside of the human body. , ... to achieve specific properties such as corrosion-resistance, biocompatibility, or operation at temperatures from ...
Breaking Biology Technology:
Cached News: